ArticleFrontiers in oncology2019
First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma-A Retrospective Study.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types.Cancer research communications · 2026Article
- Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities.Nature reviews. Cancer · 2025Review
- Adjuvant Sequential Chemotherapy for Salivary Duct Carcinomas: A Retrospective Comparative Analysis.Oncology · 2025Article
- Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective.Pharmaceutics · 2024Review
- Androgen receptor activity inversely correlates with immune cell infiltration and immunotherapy response across multiple cancer lineages.bioRxiv : the preprint server for biology · 2024Article
- 'Toxic Masculinity': What Is Known about the Role of Androgen Receptors in Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2023Review
- Transcriptome profiling for precision cancer medicine using shallow nanopore cDNA sequencing.Scientific reports · 2023Article
- Incurable advanced salivary gland tumours: a retrospective analysis and peek into the perplexing clinical and molecular intricacies from a tertiary care centre in India.Ecancermedicalscience · 2023Article
- Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling.NPJ precision oncology · 2022Article
- Demography, patterns of care, and survival outcomes in patients with salivary duct carcinoma: an individual patient data analysis of 857 patients.Future science OA · 2022Article
- Article
- Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.Therapeutic advances in medical oncology · 2022Article
- Biological roles and clinical significance of estrogen and androgen receptors in head and neck cancers.Journal of Cancer · 2022Review
- Salivary gland cancers in elderly patients: challenges and therapeutic strategies.Frontiers in oncology · 2022Review
- HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients.Frontiers in oncology · 2022Article
- Article
- Novel case of androgen receptor-positive cancer of unknown primary without serum prostate-specific antigen elevation that became progression free in the long term after primary combined androgen blockade.IJU case reports · 2021Article
- The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.Frontiers in oncology · 2021Article
- Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature.OncoTargets and therapy · 2021Article
- Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.